Pages that link to "Q71890854"
The following pages link to Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group (Q71890854):
Displaying 50 items.
- Bisphosphonates and other bone agents for breast cancer (Q24203656) (← links)
- Bisphosphonates for breast cancer (Q24246519) (← links)
- Bisphosphonates: mechanism of action and role in clinical practice (Q24644708) (← links)
- Drugs in development: bisphosphonates and metalloproteinase inhibitors (Q24795847) (← links)
- The present and future role of bisphosphonates in the management of patients with breast cancer (Q24802100) (← links)
- Actions of bisphosphonates in animal models of breast cancer (Q24802119) (← links)
- Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches (Q24806367) (← links)
- Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer (Q24811840) (← links)
- Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment (Q25255562) (← links)
- National consensus in China on diagnosis and treatment of patients with advanced breast cancer (Q26775621) (← links)
- Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases (Q26997330) (← links)
- Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? (Q28068956) (← links)
- Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma (Q28081996) (← links)
- Long-term analgesic effect of clodronate in rodents (Q28165627) (← links)
- Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial (Q28269037) (← links)
- The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel (Q28362972) (← links)
- Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone (Q28742851) (← links)
- Regression modeling with recurrent events and time-dependent interval-censored marker data. (Q30885141) (← links)
- Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. (Q31034846) (← links)
- Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial (Q32040849) (← links)
- Bisphosphonates for the relief of pain secondary to bone metastases. (Q32139406) (← links)
- Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity (Q33491284) (← links)
- Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma (Q33569980) (← links)
- Parathyroid hormone-related protein: a developmental regulatory molecule necessary for mammary gland development (Q33603548) (← links)
- Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis (Q33607167) (← links)
- Bisphosphonate treatment of lytic bone metastases (Q33630565) (← links)
- An open cohort study of bone metastasis incidence following surgery in breast cancer patients (Q33636873) (← links)
- Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain (Q33655631) (← links)
- Use of intravenous bisphosphonates in older women with breast cancer (Q33666930) (← links)
- Developments in the therapeutic applications of bisphosphonates (Q33678028) (← links)
- Clodronate: a review of its use in breast cancer (Q33737431) (← links)
- The biology and management of bone metastases (Q33757655) (← links)
- Adjuvant systemic therapy for primary breast cancer (Q33779184) (← links)
- Metastatic breast cancer (Q33779196) (← links)
- New bisphosphonates in the treatment of bone diseases (Q33785411) (← links)
- Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark (Q33801735) (← links)
- Alendronate improves QOL of postmenopausal women with osteoporosis (Q33819394) (← links)
- TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development (Q33834762) (← links)
- Antitumour effects of bisphosphonates: first evidence and possible mechanisms (Q33897197) (← links)
- Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). (Q33898576) (← links)
- Advances in pain management for older adult patients (Q33900209) (← links)
- Recent developments in bisphosphonates for patients with metastatic breast cancer (Q33935632) (← links)
- Bone metastasis in breast cancer: the role of parathyroid hormone related protein (Q33961184) (← links)
- Recent advances in cancer chemotherapy (Q33967932) (← links)
- Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies (Q33970595) (← links)
- Parathyroid hormone-related peptide and bone: pathological and physiological aspects (Q33983820) (← links)
- Effect of bisphosphonates on pain and quality of life in patients with bone metastases (Q34015944) (← links)
- Human ovarian tumor cells escape γδ T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules (Q34025938) (← links)
- Palliative care--an essential component of cancer control (Q34028975) (← links)
- Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. (Q34041808) (← links)